Primary treatment choice and response to treatment in type 1 retinopathy of prematurity (ROP)
| Parameter | Bevacizumab injection (37 eyes) | Ranibizumab injection (60 eyes) | Laser ablation (32 eyes) | Combination therapy (2 eyes) |
| ROP zone at primary treatment, eyes | ||||
| Zone I | 6 eyes | 10 eyes | 2 eyes | None |
| Posterior zone II | 10 eyes | 21 eyes | 3 eyes | None |
| Zone II | 21 eyes | 29 eyes | 27 eyes | 2 eyes |
| PMA at primary treatment, weeks | 38.4±4.2 | 36.3±2.8 | 43.5±14.1 | 37.5 |
| Anti-VEGF injection dose and numbers | ||||
| B 0.625 mg 9 eyes | R 0.2 mg 48 eyes | none | B 0.5 mg 1 eye | |
| B 0.5 mg 12 eyes | R 0.1 mg 12 eyes | none | B 0.25 mg 1 eye | |
| B 0.325 mg 6 eyes | none | |||
| B 0.2 mg 10 eyes | none | |||
| Periods of plus disease disappearance after primary treatment, days | 11.6±8.4 | 14.7±14.5 ~ not disappear | 34.1±26.2 | 14 |
| Additional treatment-requiring eyes | 10 eyes (27.03%) | 25 eyes (41.67%) | None | None |
| Duration of additional treatment after primary treatment, days | 38.6±9.8 | 71.8±38.0 | – | – |
Values of gestational age, birth weight, PMA at primary treatment, periods of plus disease disappearance and duration of additional treatment in each subgroup are presented as mean±SD.
anti-VEGF, antivascular endothelial growth factor.B, bevacizumab; PMA, postmenstrual age; R, ranibizumab;